Article
Infectious Diseases
Pei Li, Zhishuang Yang, Ting Lei, Yujie Dai, Yang Zhou, Dekang Zhu, Hongyan Luo
Summary: This study elucidated the role of a novel carbapenem-hydrolysing class D beta-lactamase RAD-1 from Riemerella anatipestifer. The RAD-1 enzyme showed distinct characteristics from other class D beta-lactamase and was widely prevalent and conserved in R. anatipestifer. Expression of RAD-1 in E. coli resulted in increased resistance to various beta-lactam antibiotics.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Biochemistry & Molecular Biology
Alicja Sloczynska, Matthew E. Wand, Stefan Tyski, Agnieszka E. Laudy
Summary: The study revealed the widespread presence of CHDL-type carbapenemases and insertion elements upstream of bla(CHDL) genes among Polish A. baumannii clinical isolates, contributing significantly to their carbapenem resistance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Infectious Diseases
Shikai Wu, Yu Feng, Yongqiang Yang, Kairong Zhu, Siyao Wang, Xinyue Wang, Guo-Bo Li, Zhiyong Zong
Summary: A new carbapenem-resistant Escherichia coli strain was found and a novel carbapenemase, OXA-1041, was identified. OXA-1041 showed preferential activity against ertapenem and was encoded on a self-transmissible plasmid. The study provides important insights into the genetic basis of carbapenem resistance.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Immunology
Tong Wang, Yu Zhu, Wenwen Zhu, Mei Cao, Quhao Wei
Summary: This study investigated the distribution of common carbapenemase genes and class 1 integron in clinical CRE isolates. It found that integrons play important roles in the emergence and spread of CRE resistance. Different subtypes of carbapenemase genes and class 1 integron were identified. The resistant rates of integron positive CRE isolates to ceftazidime, amikacin, trimethoprim/sulfamethoxazole, and gentamicin were higher than those without integrons.
MICROBIAL PATHOGENESIS
(2023)
Article
Immunology
Chongmei Tian, Jianqin Song, Lingzhi Ren, Delian Huang, Siwei Wang, Liping Fu, Yaping Zhao, Yongfeng Bai, Xueyu Fan, Tianhong Ma, Junjie Ying
Summary: The isolation of a carbapenem-resistant A. johnsonii AYTCM strain from sputum in China in 2018 is reported. The strain co-produced the NDM-1, OXA-58, and PER 1 enzymes, and exhibited resistance to multiple antibiotics. Whole-genome sequencing revealed the presence of 11 plasmids, with bla(OXA-58) and bla(PER-1) genes located on the pAYTCM-1 plasmid. The study highlights the importance of early surveillance to prevent the spread of high-risk clones in healthcare settings. Rating: 7
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Pharmacology & Pharmacy
Xi Li, Xiaofan Zhang, Heng Cai, Yiwei Zhu, Jingshu Ji, Tingting Qu, Yuexing Tu, Hua Zhou, Yunsong Yu
Summary: Sequence type 235 (ST235) Pseudomonas aeruginosa, associated with high morbidity and mortality, has a relatively high resistance to ceftazidime-avibactam (CZA), partly due to overexpression of blaGES-1 carried in a complex transposon. Overexpression of blaGES-1 combined with an efflux pump results in high-level CZA resistance, reducing therapeutic options for treating infections caused by ST235 P. aeruginosa. Surveillance initiatives are essential to prevent further dissemination of high-risk ST235 P. aeruginosa with CZA resistance.
DRUG RESISTANCE UPDATES
(2023)
Article
Infectious Diseases
Jacqueline Findlay, Laurent Poirel, Maxime Bouvier, Patrice Nordmann
Summary: This study investigated the resistance mechanisms of carbapenemase-producing Acinetobacter baumannii and evaluated the in vitro antibacterial activity of sulbactam combined with durlobactam. The results showed that sulbactam-durlobactam had excellent activity against A. baumannii isolates and identified potential mechanisms involved in resistance, including PBP substitutions and specific beta-lactamase production.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2022)
Article
Microbiology
Julian Sommer, Kristina M. Gerbracht, Felix F. Krause, Florian Wild, Manuela Tietgen, Sara Riedel-Christ, Janko Sattler, Axel Hamprecht, Volkhard A. J. Kempf, Stephan Goettig
Summary: The study identified OXA-484 as a carbapenemase with high sequence similarity plasmids, showing low frequency in horizontal gene transfer. OXA-484 exhibits antibiotic activity between OXA-232 and OXA-244, demonstrating unique resistance characteristics.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Infectious Diseases
Chyi-Liang Chen, Rajendra Prasad Janapatla, Anna Dudek, Yan-Ru Chen, Hao-Yuan Lee, Cheng-Hsun Chiu
Summary: This study aimed to evaluate the distribution and function of contact-dependent growth inhibition (CDI) systems associated with carbapenem-resistant Acinetobacter baumannii (CRAB) isolates. Results showed that the newly identified cdiTYTH1 CDI system was widespread in CRAB clinical isolates in Taiwan and may serve as an epidemic genetic marker for CRAB. In vitro bacterial competition assays demonstrated the functional role of cdiTYTH1 in inhibiting the growth of CRAB.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Infectious Diseases
M. Ishrat Jahan, Md Mizanur Rahaman, M. Anwar Hossain, Munawar Sultana
Summary: This study aimed to analyze the molecular basis of carbapenem resistance in Acinetobacter baumannii strain DMC-32a, revealing the presence of multiple resistance mechanisms including four classes of beta-lactamases and genes encoding aminoglycoside-modifying enzymes. The co-existence of such diverse resistance mechanisms highlights the need for effective therapeutics for critically ill patients and for controlling hospital-acquired infections.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2021)
Review
Pharmacology & Pharmacy
Amer El-Ghali, Ashlan Kunz J. Coyne, Kaylee Caniff, Callan Bleick, Michael J. Rybak
Summary: SUL-DUR is a novel beta-lactam-beta-lactamase inhibitor designed for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections. The FDA's fast-track approval for SUL-DUR is pending after the completion of the phase III ATTACK trial, which showed that SUL-DUR was non-inferior to colistin with a better safety profile. With limited treatment options available, SUL-DUR holds promise for the treatment of CRAB infections.
Article
Infectious Diseases
Andrea Vila Dominguez, Irene Molina Panadero, Younes Smani
Summary: This study evaluated the efficacy of clavulanic acid in combination with tazobactam against carbapenem-resistant Acinetobacter baumannii. The combination showed synergy and bactericidal effects against the bacteria, providing a potential alternative strategy for treating A. baumannii infections.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Arnon Chukamnerd, Kamonnut Singkhamanan, Virasakdi Chongsuvivatwong, Prasit Palittapongarnpim, Yohei Doi, Rattanaruji Pomwised, Chanida Sakunrang, Kongpop Jeenkeawpiam, Mingkwan Yingkajorn, Sarunyou Chusri, Komwit Surachat
Summary: This study conducted whole-genome sequencing to understand the molecular epidemiology of carbapenem-resistant Acinetobacter baumannii (CRAB) in Southern Thailand. The most prevalent sequence type (ST) was ST2 and almost all isolates carried the bla(OXA-23) gene. Various antimicrobial resistance genes, mobile genetic elements, and virulence genes were identified. These findings provide crucial information for the control and treatment of CRAB infections.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2022)
Article
Immunology
Mi Liu, Jing Liu, Jie Ma, Wanxiang Li, Xue Zhao, Wei Jia, Shirong Li
Summary: This study investigated the distribution of class 1 integrons and their variable regional molecular characteristics in CR-Eco strains, as well as the diversity of promoter types and drug sensitivity. The positive rate of class 1 integrons in CR-Eco strains was high, and these strains showed significant resistance to multiple antimicrobial drugs. The findings provide valuable insights into the mechanisms and transmission of drug resistance in these strains.
MICROBIAL PATHOGENESIS
(2022)
Article
Immunology
Pranita D. Tamma, Samuel L. Aitken, Robert A. Bonomo, Amy J. Mathers, David van Duin, Cornelius J. Clancy
Summary: The Infectious Diseases Society of America (IDSA) has provided updated guidance on the treatment of antimicrobial-resistant infections, focusing on treating AmpC-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. The guidance is based on clinical experience, expert opinion, and a review of available literature, as published data on optimal treatment options are limited. This document emphasizes treatment approaches for infections in the United States, considering differences in resistance epidemiology and the availability of specific anti-infectives internationally.
CLINICAL INFECTIOUS DISEASES
(2022)
